Repository navigation
Conversation
|
Claude encountered an error after 0s —— View job I'll analyze this and get back to you. |
Curates the syndrome rather than its tumours: the germline lesion, the two-hit mechanism, the 2022 diagnostic criteria, the tumour spectrum as phenotypes, mosaicism as its own inheritance block, surveillance and outcome. The constituent tumours stay in Acoustic_Neuroma, Meningioma, Schwannoma and Ependymoma. Six pathophysiology nodes, 21 pathograph nodes and 17 edges with no orphan targets, 7 of 10 phenotypes wired, 93 verified snippets over 20 publications plus the ClinGen Definitive gene-disease validity record for NF2. Three discussions, one of them a CONTROVERSY: two full-text papers disagree about whether merlin acts on LATS at the plasma membrane or in the nucleus, and each argues against the other by name, so the edge from merlin loss to YAP activation is INDIRECT_KNOWN_INTERMEDIATES. Closes #17397 Co-Authored-By: Claude Opus 5 <noreply@anthropic.com>
2e031fd to
f9a1068
Compare
|
Claude finished @cbhindex's task in 1m 48s —— View job Review of PR #17478: changes requestedI submitted a REQUEST_CHANGES review. Overall this entry is strong: all 93 snippets verify against the cached references, the 25 changed files all belong to this entry, the pathophysiology nodes are atomic, and the ontology terms are good. Two things block it.
🟡 Blocking
🔵 Suggestions
|
There was a problem hiding this comment.
Review: NF2-Related Schwannomatosis
This is a well-built entry. The six-node chain is atomic, the membrane-vs-nucleus controversy is handled honestly, and the frequency bands are well calibrated. It is still blocked on two things. First, the GeneReviews chapter is only partly mined: nothing from its Diagnosis, Management or Surveillance sections is used, and Management includes a radiation warning that the entry contradicts by omission. Second, the PR leaves a statement in Neurofibromatosis.yaml that will be false once this merges.
- Schema validation would pass (author's
just validate; scope is clean: 25 files, all belonging to this entry) - All PMIDs verified as real (every cited reference is cached; titles spot-checked against cache)
- Evidence snippets are exact quotes (
count-verified-snippets: 93/93) - Ontology terms correct and specific (HP:0009589, HP:0002888, NCIT:C25598, CL triple on the second-hit node all look right)
- evidence_source classifications correct
- No pathophysiology bundling
🟡 IMPORTANT
1. GeneReviews is mined only for Clinical Characteristics and inheritance (review rubric item 15). PMID:20301380 is tagged and cited 6 times. None of those citations come from its Diagnosis or Management sections:
- Agents/circumstances to avoid. GR says: "Radiation therapy of NF2-associated tumors, especially in childhood, when malignancy risks are likely to be substantially higher." The
Stereotactic radiosurgeryrow says nothing about malignancy risk or avoiding radiation in children. Clinically, this is the most important gap. Add a GR evidence item and a caveat on that treatment. - Diagnosis/Testing. The
Diagnostic criteria, 2022 revisiondescription paraphrases GR almost word for word ("bilateral vestibular schwannomas, an identical NF2 pathogenic variant identified in two or more anatomically distinct NF2-related tumors…") but cites other papers for it. Cite GR for that sentence. - Surveillance. The MRI row takes its interval from a review of sporadic vestibular schwannoma (
PMID:32232723, graded INDIRECT for that reason). GR gives the syndrome's own surveillance schedule: "annual brain MRI beginning at approximately age ten to 12 years…; annual hearing evaluation, including BAER testing; annual complete ophthalmology examination." Use it. A surveillance/monitoring treatment row would hold it naturally. - Genetic counseling. The mosaic block says transmission risk is "below the dominant one", but GR's explicit statement is not quoted: "offspring of an individual with a germline pathogenic variant have a 50% chance of inheriting the variant, while offspring of an individual who has mosaic NF2 may have a less than 50% risk".
2. Neurofibromatosis.yaml NF2 subtype row (line ~150) becomes false on merge. It says the entity "is currently uncurated as a standalone dismech entry". The fix is one line: add curated_in: NF2-Related_Schwannomatosis and trim that sentence. Please do it in this PR. Deferring it guarantees a window where the KB contradicts itself, and the repo's strictness policy asks for fixable problems not to be pushed to a follow-up. (The Schwannomatosis.yaml MONDO:0008075 scope question is different: it genuinely needs another curator's or MONDO's decision, and logging it is the right call.)
3. No deep-research artifact. The review skill expects at least one research/*-deep-research-*.md for a new entry. The entry is clearly thorough, so this is a process point. Either run one (and check it against the entry), or have a maintainer waive the requirement explicitly.
🔵 SUGGESTIONS
- Hearing rehabilitation. GR lists audiology referral, cochlear and auditory brainstem implants, and lipreading/sign language. ABI is a defining NF2-specific intervention and is absent. Also consider GR's bevacizumab-for-ependymoma line, and its "average age of onset is 18 to 24 years" as an onset qualifier.
YAP and TAZ Activationbinds the samehippo signalingDECREASED as its upstream node, so the two nodes look identical by term. Consider binding the downstream effect instead, e.g. a TEAD/YAP-dependent transcription process if GO has a fitting term. Otherwise leave this node's process unbound and let the description carry it.- Repository-state prose in
notes:will go stale. Examples: "Twenty publications are cited… Nine of the twenty are cached as full text", and "The local build read on 21 October 2026…". The MONDO-parent fact is useful; the counts belong in the history record. Likewise, the "Written from cached sources only, by hand…" opening ofreview_notesdescribes the session, not the disease. - StatPearls Neurofibromatosis Type 2 exists (
PMID:29261934). It is optional and never a baseline.
What's good
- The three unwired phenotypes (cataract, retinal hamartoma, neuropathy) have a sound stated rationale.
- REFUTE items in the CONTROVERSY and HUMAN_MODEL_MISMATCH discussions are used correctly.
- Prevalence arithmetic checks out: 1/50,500 ≈ 2.0 and 1/27,500 ≈ 3.6 per 100k, with correct bands and denominators.
- The
GERMLINE_AND_SOMATICrationale, the ClinGen Definitive record against the entry's own MONDO term, and the decision not to claim the unnamed 1-in-33,000 figure are all careful work.
There was a problem hiding this comment.
Re-review: NF2-Related Schwannomatosis. Changes are still needed, because nothing new has been pushed
The PR head is still f9a1068f50, the same commit the earlier changes-requested review looked at. I re-checked that commit on its own. The blocking items from that review are all still present, and I agree with each of them. The content is strong: the chain is atomic, the CONTROVERSY and model-mismatch discussions are handled well, the frequency bands and prevalence arithmetic are calibrated, and the ClinGen Definitive record is filed against the entry's own MONDO term. Below is what still has to change before this can merge.
- Schema validation would pass (the author ran
just validate; all 25 changed files belong to this entry, with no reversions or out-of-scope churn) - All PMIDs verified as real (every cited reference is cached)
- Evidence snippets are exact quotes
- Ontology terms correct and specific
- evidence_source classifications correct
- No pathophysiology bundling
🟡 IMPORTANT (blocking)
1. Only part of the GeneReviews chapter is used. just check-genereviews reports TAGGED for PMID:20301380. All six citations of it come from the Clinical Characteristics and inheritance sections: autosomal dominant inheritance, de novo mosaicism, bilateral VS by age 30, the definition sentence, childhood presentation, and mononeuropathy. The cached abstract has three more sections that are never quoted:
- Agents/circumstances to avoid. The chapter says to avoid "Radiation therapy of NF2-associated tumors, especially in childhood, when malignancy risks are likely to be substantially higher." The
Stereotactic radiosurgeryrow (line ~1383) does not mention this. It is the most clinically important omission. Add the GR evidence item and a caveat to that row. - Surveillance. The chapter gives the syndrome's own schedule: annual neurologic exam, annual brain MRI from about age 10–12, annual hearing evaluation including BAER, and annual ophthalmology exam. Quote it. At the moment the MRI interval rests on a review of sporadic VS (PMID:32232723, graded INDIRECT).
- Diagnosis/testing. The description in the 2022-criteria diagnosis row closely tracks the GR wording, but it cites other papers. Cite GR as well.
- Genetic counseling. Quote GR's 50% versus "less than 50%" transmission-risk sentence for mosaic parents on the mosaic inheritance block. That block currently states the claim without a source.
2. kb/disorders/Neurofibromatosis.yaml line 150 will become false once this merges. It still says NF2 is "currently uncurated as a standalone dismech entry". Add curated_in: NF2-Related_Schwannomatosis to that subtype row and trim the sentence. This is a one-line change and belongs in this PR.
3. No deep-research artifact. A new entry needs one. research/Schwannomatosis-deep-research-falcon.md is about the non-NF2 disease and does not count. Either run a report for this entry and cross-check it against the YAML, or get a maintainer to waive the requirement explicitly on this PR.
🔵 SUGGESTIONS
- Add hearing rehabilitation, especially the auditory brainstem implant, which GR lists and which is specific to NF2. GR also gives an average onset age of 18–24 years, which you could use as an onset qualifier.
YAP and TAZ Activationbinds the samehippo signalingDECREASED term as its upstream node. Bind the downstream transcriptional effect instead, or leave the process unbound.- Some prose describes repository or session state ("Twenty publications are cited…", "The local build read on…", and the opening of
review_notes). Move it to the history record. - A StatPearls chapter exists (PMID:29261934). Citing it is optional, and it is never a baseline.
Please address everything in a single push. The approval gate clears when a re-review approves the new head.
The review's blocking finding was that the chapter was used only for Clinical Characteristics and inheritance, and that its Management section carries a radiation warning the entry contradicted by omission. Four citations from the sections that were skipped. The agents-to-avoid statement - radiation of NF2-associated tumours, especially in childhood, where malignancy risk is judged substantially higher - is now a REFUTE item on the stereotactic radiosurgery row, with the caveat in its description. The chapter's own statement of the three diagnostic routes goes on the criteria row, which had paraphrased it while citing other papers. The surveillance schedule gets a treatment row of its own, because it follows the syndrome rather than one known tumour. And the explicit transmission figures go on the mosaic inheritance block. A hearing-rehabilitation row is added: auditory brainstem implantation is the option this syndrome needs and most causes of deafness do not, because the tumours and their surgery destroy the cochlear nerve a cochlear implant requires intact. Neurofibromatosis.yaml said its NF2 subtype is uncurated as a standalone entry, which this PR makes false. It now carries curated_in and corrected prose, here rather than in a follow-up, so no window exists in which the KB contradicts itself. Two suggestions taken. The YAP and TAZ node bound the same hippo signaling DECREASED as the node above it; it now binds its own effect. And the source census and the dated MONDO-build mechanics are out of notes and into the history record, since both described the repository rather than the disease. NCIT has no surveillance term inside the clinical-intervention tree: C15719, C61256, C48261 and C53607 all exist and none is reachable from C25218, so the row binds Observation Activity and the note records the searches. 98 snippets verified, 19 offline gates green. Co-Authored-By: Claude Opus 5 <noreply@anthropic.com>
|
Both blocking items are done, plus two of the suggestions. One item I can't satisfy myself and need a maintainer's call on — it's the last section below. 1. GeneReviews mined beyond Clinical CharacteristicsYou were right that the chapter was used for one section and the most clinically important thing in it was missing.
2. Hearing rehabilitationAdded, and you were right that it is NF2-specific rather than generic: the brainstem implant is needed here precisely because bilateral vestibular schwannomas and their surgery destroy the cochlear nerve that a cochlear implant requires intact. The row states the options without outcomes, because the chapter lists availability and does not rank them. A note on its binding, since it is the kind of thing worth recording: NCIT has no term for auditory brainstem implantation, and the device terms are not clinical actions so cannot sit in a The same problem bit the surveillance row harder. 3.
|
New entry for NF2-related schwannomatosis, the syndrome rather than its tumours.
Acoustic_Neuroma,Meningioma,SchwannomaandEpendymomaalready carry thebiology of the constituent tumours, so this curates what they do not: the germline
lesion, the two-hit mechanism, the 2022 diagnostic criteria, the tumour spectrum as
phenotypes, mosaicism, surveillance and outcome.
Closes #17397.
There is no stub to delete and no research report to commit.
What it contains
merlin-dependent growth restraint, YAP and TAZ activation, schwannoma formation,
mass effect on the eighth nerve. Seven of ten phenotypes hang off it.
Schwann, meningothelial and ependymal — and both NF2-bearing nodes bind merlin's
signalling adaptor activity.
dominant block: a large minority of patients are mosaic, their disease is milder,
later and more asymmetrical, and their transmission risk is below the dominant one.
gene_disease_validityblock against this entry's own MONDO term.CONTROVERSY: two full-text papers disagree aboutwhere merlin acts on LATS, one placing it at the plasma membrane and the other
concluding it acts largely if not exclusively in the nucleus, each arguing against
the other by name. The edge from merlin loss to YAP activation is
INDIRECT_KNOWN_INTERMEDIATESfor that reason — the intermediates are known andtheir order is not.
Three phenotypes are deliberately not wired
The cataract, the retinal hamartoma and the neuropathy are left causally
unconnected. The reviews list them as manifestations and the criteria count them as
signs; no cited source says what produces them. An edge from the merlin node to a
lens opacity would assert a mechanism nothing here supports.
What is left out
The entry records that the second hit happens, and how often biallelic loss is found
in patients' schwannomas, but not the chromosomal mechanism by which the remaining
allele is lost. That is a gap, not an oversight, and a follow-up can close it.
Two scope questions, logged and not settled
Neither blocks this PR and neither touches a file this PR changes.
kb/disorders/Schwannomatosis.yamlbindsMONDO:0008075, which MONDO's currentrelease makes the parent of this entry's term — but that entry is written as the
non-NF2 disease, with "non-NF2 schwannomatosis" among its synonyms and only
SMARCB1- and LZTR1-related subtypes. After MONDO's move the entry bound to the
parent class explicitly excludes what MONDO files as its child. MONDO is also
internally inconsistent here:
MONDO:0008075's own definition excludes vestibularinvolvement while the class is the asserted parent of a disease whose defining
feature is bilateral vestibular schwannoma. The fix is that curator's to choose,
and may belong upstream.
Neurofibromatosis.yamlcarries an NF2 subtype row bound to this entry's termwhose description says the entity "is currently uncurated as a standalone dismech
entry". That becomes false when this merges and needs a
curated_in:pointer.Verification
Two adversarial passes ran before this push, split by axis, each given the entry and
its sources but not the reasoning behind them. Between them they found five claims
every automated gate accepted. Four were statements that something does not exist,
refuted by the ontologies or by a source the entry itself cites:
HP:0002888 Ependymoma, two levels below the term boundHP:0009589, a child of the term boundNCIT:C25598 Observation Activityis inside it, andAcoustic_Neuromaalready uses itThe fifth said no cited source measures how often the second hit occurs; a cited
paper puts biallelic NF2 loss at about 60% of patients' schwannomas. All five are
repaired and the three ontology terms rebound.
Also corrected: a prevalence band an order of magnitude out against its own rate; a
VERY_FREQUENTband on hearing impairment that no cited source supports (removed,for the same reason the tinnitus row carries none); a stated source count of
thirty-seven against an actual nineteen; two mouse results graded
DIRECTfor anedge neither quote names; a protocol paper's own data graded
REVIEW_SYNTHESIS; aresult resting on in vivo Drosophila graded
IN_VITRO; apreferred_termbroaderthan the term it was bound to; and three explanations claiming more than their
quotes said.
The GeneReviews chapter
check-genereviewsreported asUNTAGGED_CHAPTERis nowcited for the phenotype baseline and tagged in
references:.Validation
just validate— schema, terms and references clean; 93 snippets and 94 titles verified,0 issues
check-gene-activity-grounding, which thisentry failed until both NF2-bearing nodes bound merlin's signalling adaptor
activity
just check-genereviews --strictclean for GeneReviewsjust list-disconnected-phenotypes— 7 of 10 connected🤖 Generated with Claude Code